Therapeutic Lead Discovery
Hybridoma → BLI characterization
16 weeks, antigen to confirmed leads
- Antigen design and production
- Four-mouse immunization campaign
- 20 plates screened by ELISA
- 55 top hits confirmed by FACS and BLI
Case Studies
These are the campaigns whose figures we are free to publish. They are a small part of the lab's project history — most of what we run stays confidential, and client identities are withheld throughout.
Hybridoma → BLI characterization
16 weeks, antigen to confirmed leads
Yeast display → kinetics
8 weeks, parent clone to variants
Existing LC → yeast display → kinetics
6 weeks, library to functional hits
The three above are the ones with publishable data. The list below is what the lab actually spends its time on, across every service line, and it is a good deal longer than four projects.
| Discovery | Fully human leads from transgenic mouse campaigns; VHH and scFv panels raised by phage display against targets that resist immunization; paired VH/VL panels from single-B cell sorting; multi-epitope panels screened for sandwich pairs. |
|---|---|
| Engineering | Humanization of rodent leads; developability repair on clones carrying sequence liabilities; engineering for species cross-reactivity; conversion between IgG, Fab, scFv and bispecific formats. |
| Production | Antigen production for immunization and screening; bacterial constructs recovered from inclusion bodies by refolding; Fc fusions, multi-domain and glycosylated proteins in mammalian systems. |
| Characterization | Kinetics on clones supplied by the client; epitope binning across whole panels; HDX-MS epitope mapping; thermal stability and aggregation screening. |
| Functional | Reporter and stable overexpression lines built to spec; receptor blocking on cells; in vivo imaging in tumor-bearing models; PK/PD run alongside efficacy in the same study. |
If one of these looks like your situation, say so — it shortens the scoping conversation considerably.
Request a quotation